Clinical trials: Enteric Fever
Intestinal Permeability, Inflammation
Induction of Gut Permeability by an Oral Vaccine
This study evaluates the effect of an oral typhoid vaccine on disruption of the intestinal barrier and response of the immune system.
- Conditions
- Intestinal Permeability, Inflammation, Vaccine, Typhoid Fever
- Trial name
- NCT04083950
- Testing
- Vivotif Typhoid Oral Vaccine, Aspirin (Positive Control)
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- USDA, Western Human Nutrition Research Center
Typhoid
Safety, Reactogenicity and Immunogenicity of Vi-DT;Typhoid Conjugate Vaccine
This is a randomized, observer-blinded Phase 2 study in healthy infants and toddlers 6-23 months of age at the time of the first vaccine dose.
- Trial name
- NCT03527355
- Testing
- Vi-DT, FluQuadri™, 0.9% sodium chloride isotonic solution
- Where
- Philippines
- Volunteers
- 285 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Typhoid
Immune Non-inferiority and Safety of a Vi-DT Typhoid Conjugate Vaccine
This is a Multicenter, observer-blinded, randomized, Active controlled, Phase 3 study in healthy 6 months to 45 years aged Nepalese at the time of the first vaccine dose. The study objectives are: I.
- Trial name
- NCT03933098
- Testing
- Test Vaccine Vi-DT Typhoid conjugate, Control Vaccine Typbar TCV®
- Where
- 4 sites in Nepal
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Typhoid Fever
Safety and Tolerability of Typhoid Conjugate Vaccine (EuTCV) in Healthy Adults
The purpose of this study is to evaluate the safety and tolerability of EuTCV, in comparison to TCV (Typbar-TCV™, Bharat Biotech) and Vi-Polysaccharide vaccine (Typhim Vi®, Sanofi Pasteur) in healthy adult volunteers.
- Trial name
- NCT03956524
- Testing
- EuTCV, Typbar-TCV™, Typhim Vi®
- Where
- Philippines
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- EuBiologics Co.,Ltd
Antibody Typhoid Vaccine
Long-Term Protection of Vi Antibodies Induced by Bio TCV in Indonesian Population Compared to PQed TCV
Typhoid fever is a serious systemic infection caused by the enteric pathogen Salmonella enterica serovar typhi. S typhi is spread by the fecal-oral route. Although largely an endemic disease, S. typhi has epidemic potential.
- Trial name
- NCT06921460
- Where
- Indonesia
- Volunteers
- 624 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma
Iron Deficiency Anemia
Iron Fortified Food to Improve Japanese Encephalitis and Typhoid Fever Vaccine Immunogenicity
Iron deficiency (ID) anaemia (IDA) is a global public health problem, with the highest prevalence in Africa and in South-East Asia.
- Trial name
- NCT06027801
- Testing
- Iron-fortified cookies, Japanese encephalitis (JE) vaccine, Typhoid Vi polysaccharide (Vi-PS) vaccine
- Where
- Thailand
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Typhoid Fever
Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Children, Older Infants and Infants
This phase 2 trial is aimed to obtain information on the safety and immunogenicity of the Vi-CRM197 in children and infants from various age groups in the Philippines where Typhoid Fever is highly endemic and an efficacious…
- Trial name
- NCT01437267
- Testing
- Vi-CRM197 vaccine, Pneumococcal conjugate vaccine, Vi Polysaccharide (PS) vaccine
- Where
- Philippines
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Novartis
Typhoid
Immunogenicity and Tolerability of Booster Typhoid Conjugate Vaccine (TCV) 5-6 Years After Initial Dose in Children in Burkina Faso
This study evaluated the persistence of immunity following primary typhoid conjugate vaccination in early childhood and assessed the immunogenicity and safety of a booster dose administered 5-6 years later.
- Trial name
- NCT07624175
- Testing
- Vi capsular polysaccharide-CRM197 conjugate vaccine (Vi-CRM), 0.5 mL IM
- Where
- Burkina Faso
- Volunteers
- 147 people, healthy volunteers welcome
- Sponsor
- Kathleen Neuzil
Typhoid Carrier, Typhoid Fever
Curcumin Extract Added to Ciprofloxacin for Typhoid Carriers Among Food Handlers of the Free Nutritious Meal Program
Some people keep carrying Salmonella Typhi after they recover from typhoid fever. These carriers have no symptoms. They can still pass the bacteria into food.
- Conditions
- Typhoid Carrier, Typhoid Fever, Salmonella Typhi Infection
- Trial name
- NCT07908030
- Testing
- Curcumin extract, Ciprofloxacin
- Where
- Indonesia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Universitas Sebelas Maret
Safety Issues, Immunogenicity
Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine in Indonesian Adults, Adolescents, Children and Infants
This study is to assess the safety and immunogenicity of Vi-DT vaccine in adults, adolescent, children and infants.
- Trial name
- NCT03460405
- Testing
- Vi-DT Vaccine, Vi Polysaccharide Vaccine, IPV Vaccine
- Where
- 2 sites in Indonesia
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma
Meningococcal Disease, Meningococcal Meningitis
A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults
This study compares the safety and immunogenicity profile of several travel vaccines given alone or concomitantly with MenACWY-CRM to healthy adults.
- Conditions
- Meningococcal Disease, Meningococcal Meningitis, Typhoid, Yellow Fever
- Trial name
- NCT01466387
- Testing
- Typhoid Vi Polysaccharide Vaccine, Yellow Fever Vaccine, Japanese Encephalitis Vaccine
- Where
- 5 sites in Czechia, Germany
- Volunteers
- 552 people, healthy volunteers welcome
- Sponsor
- Novartis
Typhoid
Non-inferiority Trial of Locally Manufactured Typhoid Conjugate Vaccine 'Typhocon' in Bangladesh
This is a double blinded, randomized-controlled, non-inferiority trial of a typhoid conjugate vaccine, Typhocon (Vi- polysaccharide conjugated to diphtheria toxoid, Vi-DT), manufactured by a local company, Incepta Vaccine…
- Trial name
- NCT05475379
- Testing
- Typhoid Vi polysaccharide-diphtheria toxoid conjugate vaccine (Vi-DT)
- Where
- Bangladesh
- Volunteers
- 630 people, healthy volunteers welcome
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Typhoid Fever, Paratyphoid Fever
Investigating Enteric Fever - Salmonella Typhi and Paratyphi Challenge Study
Enteric fever, an infection characterised by diarrhoea and rash, is most often caused by a bacteria called Salmonella enterica. After ingesting contaminated food or drink, the Salmonellae travel first to the gut, then the…
- Trial name
- NCT02192008
- Testing
- Salmonella Typhi, Salmonella Paratyphi
- Where
- United Kingdom
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Typhoid Fever
Safety and Immunogenicity of a Novel Conjugate Vaccine Against Salmonella Typhi and Salmonella Paratyphi A in Healthy Adults
A bivalent Typhoid and Paratyphoid A conjugate investigational vaccine aimed to prevent both typhoid and paratyphoid enteric fever in infants and older age groups has been developed by GlaxoSmithKline (GSK).
- Trial name
- NCT05613205
- Testing
- TYP04A Low Dose without Alum investigational vaccine, TYP04B Full Dose without Alum investigational vaccine, TYP03A Low Dose with Alum investigational vaccine
- Where
- Belgium
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Typhoid Fever
Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adult (18-40 Years Old)
This trial is aimed to evaluate the safety and immunogenicity profiles of a new Vi-CRM197 conjugate vaccine against S. Typhi in healthy human adults in comparison with the currently licensed Vi polysaccharide vaccine.
- Trial name
- NCT01123941
- Testing
- Typherix, NVGH Vi-CRM197
- Where
- Belgium
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Novartis
Enteric Fever, Acute Febrile Illness
Transcriptomic Responses for the Identification of Pathogens
Acute undifferentiated febrile infection (AUFI) is a common presenting syndrome in low-resource settings and better diagnostics are urgently needed to improve patient management and guide disease prevention interventions.
- Conditions
- Enteric Fever, Acute Febrile Illness, Typhoid, Paratyphoid Fever
- Trial name
- TRiP (NCT04878549)
- Testing
- 5-gene transcription signature
- Where
- India
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- University of Sheffield
Inflammation, Vaccine
WHNRC (Western Human Nutrition Research Center) Fiber Intervention Study
The purpose of this study is to determine if adding dietary fiber, such as inulin, to a diet that does not have enough fiber would raise the levels of potentially beneficial bacteria, such as Bifidobacterium, in the gut.
- Conditions
- Inflammation, Vaccine, Intestinal Permeability, Typhoid Fever
- Trial name
- NCT04543877
- Testing
- Inulin, Maltodextrin, Ty21a Typhoid Fever Vaccine
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- USDA, Western Human Nutrition Research Center
Salmonella Infection Non-Typhoid
Interaction Between Non-typhoid Salmonella, Host Microbiota, and Immune System During Acute Infection and Remission
Stool and blood samples from patients with a non-typhoid Salmonella infection will be collected during an observation period of six months and analyzed for changes in the microbiota diversity and composition, mutation rates in…
- Trial name
- NCT03494101
- Testing
- Blood samples, Stool samples, Clinical information
- Where
- Switzerland
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Zurich
Healthy
Cross-reactive Immunity Elicited by Oral and Parenteral Typhoid Vaccines
In a recent controlled study, the investigators explored cross-reactive immune responses against different Salmonella spp. in healthy volunteers immunized with either the oral (Vivotif® ) or parenteral (Typherix®) typhoid…
- Trial name
- Ty21a-ASC (NCT02121145)
- Testing
- Vivotif, Typherix
- Where
- 3 sites in Finland
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Helsinki University Central Hospital
Hepatitis A
Comparative Study in Healthy Adults Aged 18-50 Yrs Administered With Hepatyrix or Havrix+Typherix or Tiphim Vi, to Compare Reactogenicity & Immunogenicity
To evaluate the immunogenicity, reactogenicity and safety of Hepatyrix when compared to the concomitant administration of Typherix and Havrix, and when compared to the administration of monovalent vaccines, Havrix or Typhim Vi.
- Trial name
- NCT00197249
- Testing
- Combined Vi polysaccharide typhoid vaccine and hepatitis A vaccine- Hepatyrix
- Volunteers
- 1,034 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline